Large gap with delayed quotes
|
Last quote
10/16/2026
-
02:00:00
|
Bid
10/16/2026 -
11:59:39
|
Bid Volume |
Ask
10/16/2026 -
11:59:39
|
Ask Volume |
|---|---|---|---|---|
|
27.51
-0.39
(
-1.40% )
|
25.04
|
100 |
30.39
|
100 |
Analysis date: 13.10.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 11.09.2026.
Quality
Weak
Weak
Two stars since 13.10.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 07.08.2026 at a price of 39.95.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The stock appears oversold from a technical perspective due to its recent losses. It trades below its forty day technical trend since 04.09.2026.
4wk Rel Perf
-25.09%
-25.09%
The stock appears oversold from a technical perspective, with a four week dividend-adjusted underperformance of of 25.09% behind the SP500.
Risk
Low
Low
The stock has been on the low-sensitivity level since 08.09.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.27%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.82%.
Mkt Cap in $bn
6.09
6.09
With a market capitalization between $2 & $8bn, IMMUNOVANT is considered a mid-cap stock.
G/PE Ratio
0.16
0.16
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-15.05
-15.05
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
2.46%
2.46%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
14
14
Over the last seven weeks, an average of 14 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
126
126
For 1% of index variation, the stock varies on average by 1.26%.
Correlation
0.28
0.28
Stock movements are strongly independent of index variations.
Value at Risk
2.04
2.04
The value at risk is estimated at USD 2.04. The risk is therefore 7.10%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
01.12.2023
01.12.2023